Takeda Oncology Products Summary

Product Overview

  • ALUNBRIG® (brigatinib)

    • Indication: ALK-positive metastatic non-small cell lung cancer (NSCLC)
    • Patent Expiry: November 2035
    • Status: ~10 years of patent protection remaining

  • FRUZAQLA® (fruquintinib)

    • Indication: Metastatic colorectal cancer (mCRC), third-line or later
    • Patent Expiry: Early-to-mid 2030s (estimated)
    • Status: Recently launched (November 2023)

  • ICLUSIG® (ponatinib)

    • Indication: CML (resistant/intolerant), Ph+ ALL, newly diagnosed Ph+ ALL
    • Patent Expiry: January 2027 (primary), March 2031 (extended for newly diagnosed Ph+ ALL)
    • Status: ~1 year until primary patent expiry; generics expected 2027-2028

  • NINLARO® (ixazomib)

    • Indication: Multiple myeloma (at least one prior therapy)
    • Patent Expiry: November 2029
    • Status: ~4 years of patent protection remaining

  • VELCADE® (bortezomib)

    • Indication: Multiple myeloma, mantle cell lymphoma
    • Patent Expiry: 2017-2022 (already expired)
    • Status: GENERIC AVAILABLE; multiple manufacturers in market

Patent Cliff Timeline

  • 2017-2022: VELCADE patents expired; generics dominate market
  • 2027: ICLUSIG primary patent expiry
  • 2029: NINLARO patent expiry; major revenue impact expected
  • 2031: ICLUSIG extended exclusivity expires
  • ~2030s: FRUZAQLA estimated patent expiry
  • 2035: ALUNBRIG patent expiry

Key Insights

  • Most Patent-Secure Product: ALUNBRIG until 2035
  • Nearest Patent Cliff: ICLUSIG in 2027
  • Already Generic: VELCADE experiencing 80% sales decline
  • Newest Product: FRUZAQLA (launched November 2023)
  • Largest Revenue Product: NINLARO (projected ~$585M in FY2024, facing patent expiry in 2029)